Tanzeum (albiglutide) approved, then withdrawn three years later

GlaxoSmithKline's albiglutide, sold as Eperzan in Europe, won marketing authorization from the European Commission on March 21, 2014, for treating type 2 diabetes ^[1]. In the United States it was marketed under the brand name Tanzeum. But the drug never built a meaningful share of the growing GLP-1 market, and GSK later moved to pull it. On October 29, 2018, the European Commission formally withdrew Eperzan's marketing authorization at GSK's own request, with the company citing commercial reasons ^[1]. A review article on GLP-1 receptor agonists confirms that albiglutide "was also approved, but has been withdrawn for commercial reasons," placing it alongside other GLP-1 drugs used in the U.S. and worldwide such as dulaglutide, liraglutide, exenatide, and semaglutide ^[2].

Albiglutide was a once-weekly injectable that worked by fusing GLP-1 to human albumin, a design meant to slow the drug's breakdown in the body so it needed less frequent dosing ^[2]. It belonged to the same broad drug class as Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), and older drugs like Byetta (exenatide) and Victoza (liraglutide) ^[2]. Despite being a legitimate once-weekly option, it could not compete once other GLP-1 drugs, including once-weekly semaglutide and dulaglutide, became available with what the medical literature describes as more favorable efficacy and safety profiles ^[2].

The European withdrawal notice does not give a sales figure or state exactly why doctors and patients moved away from albiglutide, only that GSK discontinued it "for commercial reasons" ^[1]. The sources do not specify U.S. sales figures, market share numbers, or the exact date Tanzeum stopped being sold in American pharmacies; that detail is not available in the material reviewed here.

Why it matters for patients

For people with type 2 diabetes who were prescribed Tanzeum before 2018, the withdrawal meant they eventually had to switch to a different GLP-1 drug or another type of diabetes medication. The clinical literature notes this kind of change is not unusual: pharmacy data cited in one review show that up to one-fourth of patients switch from their initial GLP-1 receptor agonist to a different glucose-lowering drug within the first year of treatment, for various reasons ^[2]. Because GLP-1 drugs differ in molecular structure, dosing frequency, and how they are taken, switching between them is described in the medical literature as something that typically requires guidance from a health care provider rather than a simple one-to-one substitution ^[2].

The Tanzeum story is also a case study in how the GLP-1 drug market has consolidated. Several drugs approved around the same era, including exenatide, liraglutide, and lixisenatide, are now dosed once or twice daily and coexist with newer once-weekly options like semaglutide and dulaglutide, each with its own molecular weight, half-life, and dosing schedule ^[2]. Patients considering any GLP-1 medication may want to be aware that market availability of a specific brand is not guaranteed to be permanent, even after FDA or EMA approval.

What happens next

The sources reviewed do not describe any current plans by GSK or others to revive albiglutide or bring it back to market. The EMA's public record on Eperzan was last updated on February 20, 2019, reflecting the final withdrawal, and no further regulatory action is documented ^[1]. For patients and prescribers, the practical takeaway documented in the clinical literature is that switching between different GLP-1 receptor agonists remains a recognized and sometimes necessary part of managing treatment when a specific drug becomes unavailable ^[2].